Top in endocrinology: Weight loss drug in adolescents; health effects of artificial sweeteners
Click Here to Manage Email Alerts
Findings from the STEP TEENS phase 3a trial showed that adolescents with obesity who received Wegovy had a significant decrease in BMI compared with those who received placebo.
The data demonstrate the possibility of ushering in a “new era” for adolescent and pediatric obesity treatment, Claudia Fox, MD, MPH, co-director for pediatric obesity medicine at the University of Minnesota Medical School, said during a panel discussion at ObesityWeek 2022. It was the top story in endocrinology last week.
Another top story was about how non-nutritive artificial sweeteners affect the intestinal and oral microbiome in consumers.
Read these and more top stories in endocrinology below:
‘Mind-blowing’ weight loss with semaglutide extends to adolescents with obesity
Adolescents with obesity had a BMI reduction of 16.1% at 68 weeks with once-weekly Wegovy (semaglutide; Novo Nordisk) plus lifestyle intervention, results similar to those seen with adults, according to top-line results presented at ObesityWeek 2022. Read more.
Non-nutritive sweeteners alter microbiome composition, glycemia in healthy adults
Non-nutritive artificial sweeteners may alter the intestinal and oral microbiome as well as glycemic levels of healthy adults with no cardiometabolic complications, according to a study published in Cell. Read more.
New hormone-based therapies poised to expand obesity treatment options
Multiple new anti-obesity medications currently in the pipeline could expand treatment options for the disease in the coming years, according to a speaker at ObesityWeek 2022. Read more.
Mindfulness, yoga ‘as strong as drug therapy’ plus lifestyle intervention in type 2 diabetes
Mind- and body-based practices, including mindfulness-based stress reduction, qigong and yoga, are associated with a reduction in HbA1c for adults with type 2 diabetes, according to findings from a systematic review and meta-analysis. Read more.
More adipose tissue increases breast cancer risk after menopause
Higher amounts of visceral and subcutaneous adipose tissue are associated with an increased risk for breast cancer among postmenopausal women, according to a presenter at ObesityWeek 2022. Read more.